Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience

Cornea
E J HollandClara C Chan

Abstract

To describe the systemic immunosuppression protocol used at the Cincinnati Eye Institute and University of Cincinnati, and to evaluate the success, tolerability, and side effects of systemic immunosuppression in patients undergoing ocular surface stem cell transplantation (OSST). Retrospective study of all patients who had OSST from 1997 to 2007 and received follow-up for systemic immunosuppression at the Cincinnati Eye Institute. Patients were analyzed for demographics, systemic immunosuppression exposure, ocular surface stability, efficacy, and toxicity variables. A total of 225 eyes from 136 patients with a mean age of 43.6 years (range, 8.9-80.6 years) underwent OSST with systemic immunosuppression. The most common systemic immunosuppression regimen consisted of tacrolimus, mycophenolate mofetil, and a short course (1-3 months) of prednisone (102/136 patients, 75%). Prophylactic valganciclovir and trimethoprim/sulfamethoxazole (dapsone if sulfa allergy was present) were also used. Mean duration of immunosuppression was 42.1 months (range, 3.6-128 months) and mean follow-up time after OSST was 53.9 months (range, 3.6-147.3 months). At the patients' final follow-up visit, 105/136 patients (77.2%) had a stable ocular surface. ...Continue Reading

References

Dec 15, 1984·American Journal of Ophthalmology·P A TreselerF Sanfilippo
Jan 1, 1981·American Journal of Ophthalmology·J D Salisbury, B M Gebhardt
Jan 12, 2000·Current Opinion in Nephrology and Hypertension·Y F Vanrenterghem
Aug 15, 2002·Transplantation Proceedings·E S Woodle
Apr 10, 2003·Ophthalmology Clinics of North America·Joung Y KimEdward J Holland
Dec 11, 2003·Drugs·Therese M Chapman, Gillian M Keating
Jun 29, 2004·Cornea·Edward J Holland, Gary S Schwartz
Jul 20, 2007·International Ophthalmology·Khalid F Tabbara
Dec 21, 2007·The New England Journal of Medicine·Henrik EkbergUNKNOWN ELITE-Symphony Study
May 6, 2008·American Journal of Ophthalmology·Stephen C TeohRichard W J Lee
Jan 1, 2010·American Journal of Ophthalmology·Ebenezer DanielJohn H Kempen
Feb 19, 2010·Ophthalmology·Ammar MiriHarminder S Dua

❮ Previous
Next ❯

Citations

Dec 12, 2012·American Journal of Ophthalmology·Clara C Chan, Edward J Holland
Aug 25, 2015·American Journal of Ophthalmology·Carl ShenEdward J Holland
Jun 27, 2015·BMJ Case Reports·Victoria SquissatoClara C Chan
Aug 3, 2016·The Ocular Surface·Jennifer RossenAli Djalilian
Oct 16, 2016·Journal français d'ophtalmologie·V KocabaC Burillon
Apr 6, 2017·Current Opinion in Ophthalmology·Albert Y Cheung, Edward J Holland
Jul 14, 2018·Cornea·Albert Y CheungEdward J Holland
Sep 6, 2019·Stem Cells Translational Medicine·Vincent M BorderieHélène Rouard
Jun 24, 2017·Cornea·Lorena SepsakosEdward J Holland
Nov 28, 2017·Seminars in Ophthalmology·Jia Yin, Ula Jurkunas
Dec 6, 2019·Stem Cells Translational Medicine·Catherine J JacksonTor P Utheim
Jul 28, 2018·Journal of Ophthalmology·Ying DongRobert M Lavker
Jan 5, 2020·Stem Cell Research & Therapy·Francisco BandeiraJodhbir S Mehta
Dec 17, 2020·Asia-Pacific Journal of Ophthalmology·Geetha IyerHiren Matai
Mar 24, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Jyoti SharmaNirbhai Singh
Jul 6, 2021·Frontiers in Medicine·Tais Hitomi WakamatsuJosé Álvaro Pereira Gomes
Dec 31, 2017·Survey of Ophthalmology·Wei ZhongDimitri T Azar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.